Welcome to our dedicated page for Maxcyte SEC filings (Ticker: MXCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MaxCyte, Inc. filings document the regulatory record for a Delaware life sciences tools company with Nasdaq-listed common stock. Its Form 8-K disclosures cover operating results and financial condition, corporate presentations, executive appointments, compensatory arrangements, listing-compliance notices, and cost-structure actions tied to workforce and operating changes.
MaxCyte proxy materials cover annual stockholder meeting matters, including director elections, board-class structure and auditor ratification. Together, the filings describe governance, capital-market status, material events, and formal disclosures related to MaxCyte’s cell-engineering platform business, Strategic Platform License model, and public-company reporting obligations.
Johnston John Joseph reported acquisition or exercise transactions in this Form 4 filing.
MAXCYTE, INC. director John Joseph Johnston received 30,421 restricted stock units, each representing one share of common stock, as part of his annual non-employee director grant. He also received a stock option for 49,579 shares at $1.13 per share, expiring in 2036. The RSUs vest on June 17, 2027, subject to continued service, bringing his direct common stock holdings to 201,581 shares.
Hemrajani Rekha reported acquisition or exercise transactions in this Form 4 filing.
MAXCYTE, INC. director Rekha Hemrajani reported equity awards consisting of restricted stock units and stock options. She received 30,421 RSUs, each representing one share of common stock, and 49,579 stock options with a strike price of $1.13 per share, expiring on June 16, 2036. The annual grant for non-employee directors vests on June 17, 2027, subject to her continuous service, bringing her direct common stock holdings to 70,314 shares.
MAXCYTE, INC. director Stanley C. Erck received equity-based compensation in the form of restricted stock units and stock options. He was granted 30,421 RSUs, each representing one common share, and an option for 49,579 shares at an exercise price of $1.13 per share, expiring on June 16, 2036. The RSUs vest on June 17, 2027, subject to his continued service, and his direct common stock holdings after the grant total 428,749 shares.
MAXCYTE, INC. director Douglas Richard reported awards of restricted stock units and stock options as part of his compensation. He acquired 30,421 RSUs, each representing one future share of common stock, and 49,579 stock options to buy common shares at $1.13 per share.
The annual grants were made under the company’s equity grant policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, assuming he continues to serve. After the RSU grant, his direct common stock holdings total 260,998 shares.
MAXCYTE director Cynthia Collins received new equity awards. On June 17, 2026, she was granted 30,421 restricted stock units, each representing one future share of common stock, and a stock option for 49,579 shares at an exercise price of $1.13 per share, expiring in 2036. Following the grant, she directly holds 111,310 shares of common stock, and the RSUs vest on June 17, 2027 if she continues serving as a director.
MAXCYTE, INC. director Brooke William W received equity awards consisting of common stock and stock options. He was granted 30,421 shares of Common Stock in the form of restricted stock units, each representing a right to one share. These RSUs vest on June 17, 2027, if he continues serving as a non-employee director under the company’s Equity Grant Policy. He was also granted stock options for 49,579 shares of Common Stock at an exercise price of $1.13 per share, expiring on June 16, 2036. Following these awards, he directly holds 181,300 shares of Common Stock.
MAXCYTE, INC. director Patrick J. Balthrop received equity-based compensation in the form of restricted stock units and stock options. He was granted 30,421 RSUs, each representing one share of common stock, and 49,579 stock options with an exercise price of $1.13 per share. The RSU grant was made under the company’s equity grant policy for non-employee directors and is scheduled to vest on June 17, 2027, contingent on his continued service. Following the RSU grant, Balthrop directly holds 80,998 shares of common stock. The stock options, which are also directly held, are exercisable into 49,579 shares of common stock and are scheduled to expire on June 16, 2036.
MAXCYTE, INC. director Yasir B. Al-Wakeel received equity awards as part of his annual non-employee director compensation. He was granted 30,421 shares of Common Stock in the form of restricted stock units, plus stock options for 49,579 shares at an exercise price of $1.13 per share.
The RSUs and option grant were made under the company’s Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, contingent on his continued service. Following the RSU grant, he directly owns 80,998 shares of Common Stock.
MaxCyte, Inc. held its 2026 annual stockholder meeting on June 17, 2026, where investors voted on board composition and the company’s auditor. Stockholders elected three Class II directors: Patrick Balthrop, Cynthia Collins and Stanley Erck, each receiving more votes for than withheld.
Investors also ratified the Audit Committee’s selection of CohnReznick LLP as MaxCyte’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with over 70 million votes cast in favor and minimal opposition or abstentions.
MaxCyte, Inc. has regained compliance with Nasdaq’s minimum bid price rule. The company previously received a notice that its common stock had closed below $1.00 per share for 30 consecutive trading days, putting its Nasdaq Global Select Market listing at risk.
Nasdaq informed MaxCyte that for 10 consecutive business days, from May 27, 2026 to June 9, 2026, the closing bid price of its common stock was at or above $1.00. As a result, MaxCyte now complies with Nasdaq Listing Rule 5450(a)(1), and Nasdaq considers the matter closed.